Sphere Bio is an established, Life Sciences SME, focusing on single-cell analysis platforms and tools, spun out of Cambridge University in 2010. The company has successfully commercialised microfluidic hardware, consumables (biochips, reagents and chemicals) and software for the pharmaceutical industry, biotechs and academia.

As of February 25, 2025, the company evolved from Sphere Fluidics to Sphere Bio, marking our transition from a pioneering droplet-based microfluidics company to a commercial provider of integrated life sciences tools. Built on over a decade of research and development, our picodroplet-based microfluidics platforms, originally spun out from the University of Cambridge, specialize in single-cell analysis and isolation—helping researchers identify the most important cells.

With a track record of over 400 international customers, including collaborations with seven of the world’s Top 10 pharma companies, over £40 million in investment, and 135 international patents, Sphere Bio is poised for an exciting future. Our innovative solutions, including the industry-leading Cyto-Mine® and next-generation Cyto-Mine® Chroma platforms, provide ultra-high throughput functional analysis of live cells. As we continue to expand our product portfolio and global market presence, we remain committed to delivering cutting-edge tools that accelerate scientific discovery